The US FDA approved bexagliflozin, a drug belonging to the sodium-glucose cotransporter 2 (SGLT2) inhibitor family, sold in the United States under the brand name Brenzavvy™.
This drug family acts at the kidney level, promoting glucose removal through urine and thereby helping improve glycemic control in people with type 2 diabetes.
Adding new molecules within this therapeutic family widens the alternatives available alongside other SGLT2 inhibitors already used in routine clinical practice.